Department of Radiation Oncology, Memorial Sloan-Kettering Cancer Center, New York, New York 10065, USA.
Breast J. 2010 Sep-Oct;16 Suppl 1:S34-8. doi: 10.1111/j.1524-4741.2010.01001.x.
Radiotherapy has undergone significant technological advances during the last 20 years, although their use in breast cancer was relatively limited until recently. The major recent changes in the use of radiotherapy for breast cancer have been the following: the establishment of partial breast irradiation (PBI) as an option for therapy in early stage disease; the revival of hypofractionated therapies for breast only therapy; the clearer definition of the role of post-mastectomy irradiation; and the continuing investigation as to which patients having conservative surgery do not need radiation therapy. Intensity-modulated radiotherapy is still not widely accepted to be medically necessary in breast cancer, but ongoing studies may demonstrate that it will prove to be useful in treating node-positive breast cancer when wide-field nodal targets need to be included in the treatment volume. Image-guided radiotherapy will prove to be necessary for PBI by external beam to keep the irradiated treatment volumes within long-term tolerance. The optimum dose and delivery schedule for PBI is yet to be finalized. Overall, the local control rates for all breast cancer treatment scenarios are generally good, and therefore, the emphasis is now on maintaining local control while reducing toxicities from treatment. The long-term risks of breast cancer radiotherapy on subsequent cancer induction are subject to ongoing studies. Biological enhancement of the effect of radiotherapy could allow dose reduction, with presumed reductions in the toxicity of treatment. In conclusion, breast cancer radiotherapy has much to understand and optimize in the 21st Century.
在过去的 20 年中,放射治疗技术取得了重大进展,尽管直到最近,其在乳腺癌中的应用才相对有限。乳腺癌放射治疗的主要近期变化如下:确立部分乳腺照射(PBI)作为早期疾病治疗的一种选择;重新采用乳腺癌单纯放疗的短程分割治疗;更明确界定乳房切除术放疗的作用;以及继续研究哪些接受保乳手术的患者不需要放疗。调强放疗在乳腺癌中的应用仍未被广泛认为是医学必需的,但正在进行的研究可能表明,当需要将广泛的淋巴结靶区包括在治疗体积中时,它将被证明对治疗淋巴结阳性乳腺癌有用。图像引导放疗将通过外部束来证明 PBI 的必要性,以保持照射治疗体积在长期耐受范围内。PBI 的最佳剂量和治疗计划仍有待最终确定。总的来说,所有乳腺癌治疗方案的局部控制率都很好,因此,现在的重点是在保持局部控制的同时降低治疗的毒性。乳腺癌放疗对随后癌症诱导的长期风险仍在进行研究。放射治疗效果的生物学增强可以允许减少剂量,从而假定降低治疗的毒性。总之,乳腺癌放射治疗在 21 世纪还有很多需要理解和优化的地方。